---

備註請放最後面 違者新聞文章刪除

1.媒體來源:
※ 例如蘋果日報、自由時報（請參考版規下方的核准媒體名單）
※ Yahoo、MSN、LINE等非直接官方新聞連結不被允許

Yahoo! News Singapore

2.記者署名:
※ 若新聞沒有記者名字或編輯名字，請勿張貼，否則會被水桶14天
※ 外電至少要有來源或編輯 如:法新社

Wong Casandra

3.完整新聞標題:
※ 標題沒有完整寫出來 ---> 依照板規刪除文章

1st shipment of Novavax COVID vaccine arrives in S'pore, to be offered from
end-May

第一批 Novavax COVID 疫苗抵達新加坡，五月底開打

4.完整新聞內文:
※ 社論特稿都不能貼！違者刪除（政治類水桶3個月)，貼廣告也會被刪除喔！可詳看版規

SINGAPORE — The first shipment of the Novavax COVID-19 vaccine arrived in
Singapore on Wednesday (4 May) and the doses will be administered from end-May,
said the Ministry of Health (MOH).

In a press statement, the MOH said it will start offering Nuvaxovid – a
protein-based vaccine – at Singapore's first joint testing and vaccination
centre at the former Bishan Park Secondary School, as well as 20 Public Health
Preparedness Clinics (PHPCs) at the end of the month.  The joint testing and
vaccination centres, slated to start operating end-May, will be a new class of
facilities offering COVID-19 testing and vaccination services. This will help
consolidate Singapore's resources, while ensuring testing and vaccination
services remain accessible to the public, said MOH.

"We are also working to onboard selected PHPCs to offer the Nuvaxovid vaccine.
Further details will be announced in the coming weeks," the ministry added.

The COVID-19 multi-ministry taskforce on 14 February accepted the
recommendation of the Expert Committee on COVID-19 Vaccination (EC19V) to
include the Novavax's Nuvaxovid vaccine under Singapore's vaccination
programme for use in those aged 18 years and above, for both COVID-19 primary
series and booster vaccination.

The US biotechnology company filed for interim authorisation with Singapore
authorities for use of the vaccine under the pandemic special access route in
November last year.

Nuvaxovid is one of two non-mRNA shots approved for use under the national
drive, alongside the inactivated CoronaVac developed by Chinese vaccine maker
Sinovac.

The two-dose vaccine is made with lab-grown copies of the spike protein that
coats the coronavirus.

It is developed differently from the messenger ribonucleic acid (mRNA) vaccines
produced by Pfizer-BioNTech and Moderna – the other two vaccines used under
Singapore's national vaccination drive – which deliver genetic instructions
for the body to make its own spike protein.

"Having considered the data on its safety, efficacy, and tolerability, the
EC19V recommends the Nuvaxovid vaccine as an acceptable alternative to the mRNA
vaccines in individuals aged 18 years and above, although the mRNA vaccines
still remain the preferred vaccines due to their higher efficacy and the
stronger immune response generated," MOH said.

Boosters and vaccinations "remain a critical part" of Singapore's COVID-19
strategy in ensuring the population is well protected against infection and
severe illness, according to MOH.

Those who are eligible for vaccinations and booster doses should receive them
as soon as possible, it reiterated.

Health Minister Ong Ye Kung wrote in a Facebook post on Wednesday, "If you are
still not vaccinated or boosted, (Nuvaxovid) is a good alternative to the mRNA
vaccines to get protected against COVID-19," adding that the shipment arrived
in Singapore in the morning.

As of Tuesday, 92 per cent of Singapore's total population have completed their
full COVID-19 vaccine regimen, while 74 per cent have received theirbooster
shots.

5.完整新聞連結 (或短網址)需放媒體原始連結，不可用轉載媒體連結:
※ 當新聞連結過長時，需提供短網址方便網友點擊

https://sg.news.yahoo.com/shipment-of...ed-from-end-may-142526091.html

(縮）
https://tinyurl.com/y6llos3n

6.備註:

有政府，會作事

※ 一個人一天只能張貼一則新聞(以天為單位)，被刪或自刪也算額度內，超貼者水桶，請注意
※ 備註請勿張貼三日內新聞(包含連結、標題等)


--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 148.168.40.5 (美國)
※ 文章代碼(AID): #1YSi6V_S (Gossiping)
※ 文章網址: https://www.ptt.cc/bbs/Gossiping/M.1651687839.A.FDC.html